Phase 4 N=37 Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis
Neurotrophic Keratitis
Primary: Corneal Epithelial Healing — 5; 28 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=131 Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
Neurotrophic Keratitis
Primary: Efficacy as Assessed by Complete Corneal Healing — 21; 16 Participants
Phase 2 N=174 Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
Neurotrophic Keratitis · Keratitis · Corneal Ulcer
Primary: Percentage of Patients Achieving Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer — 55; 58; 20; 45 percentage of subjects — p=<0.001
Phase 2 N=108 REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients
Neurotrophic Keratitis
Primary: Corneal Healing — 4; 2; 1; 2 Participants
Phase 2 N=48 Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK
Neurotrophic Keratitis
Primary: Complete Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer Defined by Central Reviewer — 70; 29; 30; 71 percentage of participants — p==0.006
Phase 2 N=113 Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
Neurotrophic Keratopathy
Primary: Mean Change From Baseline in Corneal Fluorescein Staining — -0.6; -0.9 score on a scale
N/A N=24 DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
Neurotrophic Keratitis
Primary: Number/Percentage of Patients Who Achieved Corneal Epithelial Healing at NGF0120 Week 8 (EoT NGF0120=Baseline NGF0122) and Remained Healed at Month 24 and Month 30 of…
Phase 3 N=152 Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
Keratitis · Corneal Ulcer
Primary: Number of Participants With a Reduction in Neurotrophic the Keratitis/Ulcer Area on Day28 — 37; 44 Participants
N/A N=44 Corneal Nerves Function and Structure
Diabetic Peripheral Neuropathy
Primary: Cornea Sensitivity — 0.177; 0.293 time ratio of eyelids closed vs. open — p=<0.001
Phase 2 N=20 Treatment of Corneal Neovascularization With Topical Pazopanib
Corneal Neovascularization
Primary: Heart Rate — 68.7 Beats per Minutes
N/A N=12 Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis
Atopic Keratoconjunctivitis
Primary: Ocular Symptoms and Signs Total Composite Score — 29.1; 4.7 units on a scale — p=0.002
Phase 2 N=68 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
Keratolysis
Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal
Phase 2 N=10 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
Persistent Corneal Epithelial Defect
Primary: Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 Weeks — 5 Participants
Phase 1 N=24 Topical Avastin for Treatment of Corneal Neovascularization
Corneal Neovascularization
Primary: The Size and Extent of Corneal Neovascularization Will be Measured by Computerized Image Analysis of Corneal Photographs Taken Throughout the Study. — 27.9 percent…
Phase 4 N=36 Impact of Acthar on Everyday Life of Participants With Severe Keratitis
Keratitis
Primary: Number of Participants Who Improved on the Impact of Dry Eye on Everyday Life (IDEEL) Scale [Using the Symptom Bother Module at Week 12] — 17 Participants
Phase 3 N=745 Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Tear Production — 16.6; 9.2 Percentage of eyes
N/A N=40 Sutureless Cryopreserved Amniotic Membrane Graft (ProKera) and Wound Healing After Photorefractive Keratectomy
Corneal Wound Healing
Primary: Number of Days to Complete Re-epithelialization — 4.6; 4.1 days to complete re-epithelialization
Phase 3 N=323 Mycotic Ulcer Treatment Trial I
Corneal Ulcer · Eye Infections, Fungal
Primary: Best Spectacle-corrected logMAR Visual Acuity — 0.39; 0.57 logMAR — p=0.006
Phase 3 N=357 Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
Conjunctivitis · Keratitis · Blepharitis
Primary: Signs and Symptoms Composite Score - Change From Baseline to Day 15 - PP Population — -11.63; -12.41 Scores on a scale
Phase 1 N=9 Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
Corneal Neovascularization
Primary: Incidence and Severity of Ocular Adverse Event — 0 participants
N/A N=55 TrueTear in Sjogren's Disease Patients
Dry Eye Syndromes · Sjogren's Syndrome
Primary: Schirmer Testing — 10.2; 0.8; 13.5 mm.
Phase 2 N=180 A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery
Ocular Discomfort
Primary: Change From Baseline in SANDE Scores for Frequency and Severity Assessed at 8 Weeks of Treatment. — -37.2; -35.7; -37.8; -37.3 score on a scale — p==0.974
Phase 2 N=1 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
Chemical Injuries · Unspecified Complication of Corneal Transplant · Autoimmune Diseases
Primary: Changes in Corneal Thickness at 1 Millimeter — 730; 760; 700; 720 micrometer
Phase 2 N=120 Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer
Fungal Keratitis
Primary: Best Spectacle Corrected Visual Acuity (BSCVA) 3 Months After Enrollment, Adjusting for Enrollment BSCVA in a Multiple Linear Regression Model — 0.61; 0.71 logMAR — p=0.29
Phase 1 N=165 Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries
Corneal Epithelial Defect · Diabetic Retinopathy · Penetrating Keratoplasty
Primary: Patients With Corneal Epithelial Healing Time Within 14 Days — 78; 73 participants
Phase 2 N=510 Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Keratoconus · Post-Refractive Ectasia
Primary: Change in Maximum Keratometry From Baseline to 6 Months After Treatment — 0.76; 0.97 diopters
Phase 3 N=176 Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
Atopic Conjunctivitis
Primary: Percentage of Treatment Responders — 21.3; 17.2 Percentage of Patients
Phase 3 N=330 Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
Acanthamoeba Keratitis · Fungal Keratitis
Primary: Best Spectacle-Corrected Visual Acuity — 0.614; 0.666 logMAR
Phase 2 N=150 An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
Dry Eye
Primary: Symptom Assessment in Dry Eye (SANDE) Scores — -38.8; -34.0; -32.2; -31.07 units on a scale — p==0.428
N/A N=84 Clinical Trial to Evaluate the Symptoms in Symptomatic Contact Lens Wearers Following Application of Intranasal Tear Neurostimulator Versus Control
Dry Eye Syndromes
Primary: Contact Lens Dry Eye Questionnaire (CLDEQ-8) Score in the Study Eye — 15.3; 17.2 score on a scale — p=0.116